GBBWRPM
ATOS icon

Genovese Burford & Brothers Wealth & Retirement Plan Management’s Atossa Therapeutics ATOS Stock Holding History

Genovese Burford & Brothers Wealth & Retirement Plan Management’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-60
Closed -$5K – 400
2017
Q2 		$5K Hold
60
– – ﹤0.01% 310
2017
Q1 		$9K Buy
+60
New +$15.3K ﹤0.01% 298
2016
Q3 		– Sell
-60
Closed -$45K – 424
2016
Q2 		$45K Buy
60
+2
+3% +$1.62K 0.02% 151
2016
Q1 		$53K Buy
58
+9
+18% +$8.34K 0.03% 127
2015
Q4 		$42K Buy
+49
New +$75.4K 0.02% 143

Other funds holding ATOS

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
GLA
Good Life Advisors Reading, Pennsylvania $1.6B AUM 15.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFW
Mosaic Family Wealth St. Louis, Missouri $384M AUM 21.14% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Genovese Burford & Brothers Wealth & Retirement Plan Management's ATOS Position: Q3 2017 in Review

Genovese Burford & Brothers Wealth & Retirement Plan Management sold out of Atossa Therapeutics (ATOS) in Q3 2017, closing a stake of 60 shares — an estimated $5K sold.

Genovese Burford & Brothers Wealth & Retirement Plan Management first reported a position in ATOS in Q4 2015 and held it in 5 quarters. The position peaked at $53K in Q1 2016. 11 funds tracked by Wall St. Rank hold ATOS as of Q3 2017.

  • Genovese Burford & Brothers Wealth & Retirement Plan Management reported no remaining Atossa Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Genovese Burford & Brothers Wealth & Retirement Plan Management sold 60 Atossa Therapeutics shares in Q3 2017, an estimated $5K.
  • Genovese Burford & Brothers Wealth & Retirement Plan Management first reported a position in Atossa Therapeutics in Q4 2015 and held it in 5 quarters.
  • Genovese Burford & Brothers Wealth & Retirement Plan Management's Atossa Therapeutics position peaked at $53K in Q1 2016.
  • 11 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2017.

Based on Genovese Burford & Brothers Wealth & Retirement Plan Management's 13F filing for Q3 2017, filed 8 Nov 2017.